NCT01766739View on ClinicalTrials.gov

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions
Lung Cancer
Interventions
BIOLOGICAL

GL-ONC1

Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Genelux Corporation
All Listed Sponsors
collaborator

Genelux Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01766739 - Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma | Biotech Hunter | Biotech Hunter